Valuation: NovoCure Limited

Market Cap 1.84B 1.62B 1.53B 1.39B 2.61B 177B 2.63B 18.29B 7.07B 90.23B 6.92B 6.77B 290B P/E 2026 *
-12.7x
P/E 2027 * -19.4x
Enterprise Value 1.74B 1.53B 1.44B 1.31B 2.46B 167B 2.48B 17.24B 6.67B 85.07B 6.53B 6.39B 273B EV / Sales 2026 *
2.4x
EV / Sales 2027 * 2.03x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day-2.22%
1 week-5.09%
Current month-10.25%
1 month-10.10%
3 months+5.25%
6 months+36.43%
Current year+22.51%
1 week 15.73
Extreme 15.73
16.87
1 month 15.1
Extreme 15.1
18.59
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
126.66
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 2025-11-30
Director of Finance/CFO 52 2024-12-31
Chief Tech/Sci/R&D Officer - 2023-01-16
Director TitleAgeSince
Director/Board Member 59 2011-12-31
Chairman 63 2008-12-31
Director/Board Member 64 2011-08-04
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Chief Executive Officer

1,905 0.0016%
6/30/26 Free

Head of Human Resources

1,905 0.0016%
6/30/26 Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
-2.22%-5.09%+23.94%-8.65% 1.84B
-0.26%+0.41%+27.97%+29.02% 12.56B
-0.04%+2.84%+21.78%+21.39% 6.67B
+0.87%+2.81%+38.42%+23.18% 5.68B
-2.25%-8.31% - - 5.62B
-3.88%-1.65%-26.61%+32.26% 4.9B
-1.49%+0.65%-30.56%-22.78% 3.91B
+1.37%-1.01%-10.20%+188.51% 1.69B
-0.33%+1.16%+50.25%-13.48% 1.59B
-1.90%+0.98%-17.20%+57.78% 1.35B
Average -1.01%-0.72%+8.64%+34.14% 4.58B
Weighted average by Cap. -0.89%-0.44%+13.64%+26.53%

Financials

2026 *2027 *
Net sales 726M 637M 601M 548M 1.03B 69.55B 1.03B 7.2B 2.78B 35.51B 2.73B 2.67B 114B 805M 707M 667M 607M 1.14B 77.11B 1.15B 7.98B 3.09B 39.37B 3.02B 2.96B 126B
Net income -142M -125M -118M -107M -201M -13.61B -202M -1.41B -545M -6.95B -533M -522M -22.33B -84.78M -74.43M -70.22M -63.99M -120M -8.12B -121M -841M -325M -4.15B -318M -311M -13.33B
Net Debt -105M -92.61M -87.37M -79.61M -149M -10.11B -150M -1.05B -404M -5.16B -396M -387M -16.58B -210M -184M -174M -158M -297M -20.11B -299M -2.08B -805M -10.27B -788M -771M -33B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
26-09-25 US$15.84 -2.22% 1,028,050
26-09-24 US$16.20 -0.31% 1,142,632
26-09-23 US$16.25 -2.52% 777,756
26-09-22 US$16.67 +0.85% 1,044,654
26-09-21 US$16.53 -0.96% 633,460
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
15.84USD
Average target price
27.14USD
Spread / Average Target
+71.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock